GlassScriptPhysician profile
Jeffrey Manese
NPI 1619023769
$1,801.58
in general payments reported to CMS, 2019-2025
14 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $202 · 2023: $422 · 2024: $609 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Education: $85.49 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26.20 · Travel and Lodging: $3.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.82 |
| Education | $85.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26.20 |
| Travel and Lodging | $3.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $616.37 | 2024-2025 | Vercise, General - Dbs, Suretek |
| Medtronic, INC. | $320.65 | 2022-2023 | Percept PC Brainsense |
| Neurocrine Biosciences, INC. | $202.97 | 2023-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $175.95 | 2025 | |
| Gilead Sciences, INC. | $125.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $119.83 | 2023-2024 | Austedo Xr |
| Abbvie INC. | $59.15 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $48.58 | 2024 | Xeomin |
| Acadia Pharmaceuticals INC | $27.98 | 2024 | Nuplazid |
| Amneal Pharmaceuticals LLC | $27.17 | 2024 | Crexont |
| Abbott Laboratories | $24.18 | 2024 | Infinity |
| Acorda Therapeutics, INC | $23.57 | 2024 | Inbrija |
| Sunovion Pharmaceuticals INC. | $17.72 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Manese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.